Live
- Tamil Nadu Farmers Rally At Jantar Mantar, Demand Action On Crop Prices And River Interlinking
- TDP candidate for Bapatla files nomination
- Patanjali Issues Expanded Apology In Newspapers For Misleading Advertisements
- Chief Minister Arvind Kejriwal Administered Insulin In Tihar Jail
- TS Inter results announced, here is the direct link
- Apple Announces Special Apple Event Themed 'Let Loose' for New iPads
- Chandrababu calls Chintamaneni Prabhakar, to issues B-Form
- Prathipati files nomination in Chilakaluripet
- Karumuri, Kamineni, Meka submit nominations
- Guntur: Team of retd IAS, IPS officers to check irregularities in polls
Granules gets USFDA nod for ADHD drug
Highlights
Drug firm Granules India on Monday said its subsidiary has received approval from the US health regulator for Methylphenidate Hydrochloride
Hyderabad: Drug firm Granules India on Monday said its subsidiary has received approval from the US health regulator for Methylphenidate Hydrochloride extended-release capsules, used for the treatment of attention deficit hyperactivity disorder (ADHD).
The approved product is bioequivalent to the reference listed drug product (RLD), Ritalin LA extended-release capsules of Novartis Pharmaceuticals Corporation.
The US Food and Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals, a wholly-owned foreign subsidiary of Granules India, for Methylphenidate Hydrochloride extended-release capsules in the strengths of 10 mg, 20 mg, 30 mg, 40 mg and 60 mg, Granules said.
Next Story
ADVERTISEMENT
